Compare
Fortress Biotech, Inc. vs Nuvation Bio Inc. vs Tango Therapeutics, Inc. vs Enanta Pharmaceuticals Inc
| Latest fiscal year | Fortress Biotech, Inc. FBIO | Nuvation Bio Inc. NUVB | Tango Therapeutics, Inc. TNGX | Enanta Pharmaceuticals Inc ENTA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-09-30 |
| Revenue | $63.26M | $62.90M | $62.38M | $65.32M |
| Revenue growth (YoY) | +9.7% | +699.0% | +48.3% | -3.4% |
| Gross margin | 66.9% (computed) | n/a | n/a | n/a |
| Operating margin | -111.0% | -338.7% | -178.4% | -130.7% |
| Net margin | 10.8% | -325.3% | -162.9% | -125.4% |
| Net income | $6.82M | -$204.63M | -$101.59M | -$81.89M |
| EPS (Diluted) | -$0.07 | -$0.60 | -$0.87 | -$3.84 |
| Operating cash flow | -$65.78M | -$173.43M | -$138.89M | -$19.27M |
| Free cash flow | n/a | n/a | -$139.93M | -$32.17M |
| Cash & equivalents | $79.38M | $164.09M | $112.28M | $32.30M |
| Total assets | $185.55M | $594.82M | $398.69M | $280.73M |
| Total liabilities | $123.36M | $289.11M | $52.51M | $216.01M |
| Shareholders' equity | $49.87M | $305.72M | $346.18M | $64.72M |
| Return on year-end equity | 13.7% | -66.9% | -29.3% | -126.5% |
| Shares outstanding | 31.36M | 337.84M | 135.94M | 21.39M |
Revenue, most recent five fiscal years
| Fiscal year | Fortress Biotech, Inc. | Nuvation Bio Inc. | Tango Therapeutics, Inc. | Enanta Pharmaceuticals Inc |
|---|---|---|---|---|
| Latest | $63.26M Ended 2025-12-31 | $62.90M Ended 2025-12-31 | $62.38M Ended 2025-12-31 | $65.32M Ended 2025-09-30 |
| 1 year earlier | $57.67M Ended 2024-12-31 | $7.87M Ended 2024-12-31 | $42.07M Ended 2024-12-31 | $67.64M Ended 2024-09-30 |
| 2 years earlier | $84.51M Ended 2023-12-31 | $0 Ended 2023-12-31 | $36.53M Ended 2023-12-31 | $79.20M Ended 2023-09-30 |
| 3 years earlier | $75.74M Ended 2022-12-31 | n/a | $24.86M Ended 2022-12-31 | $86.16M Ended 2022-09-30 |
| 4 years earlier | $68.79M Ended 2021-12-31 | n/a | $37.04M Ended 2021-12-31 | $97.07M Ended 2021-09-30 |